chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Product dose omission issue, Pruritus, Urticaria, Vaccination site pain
Clinical narrative: Redness on neck and chest; Hives/Welts; Soreness in injection arm; Itchiness; Missed second dose; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (Redness on neck and chest), URTICARIA (Hives/Welts), VACCINATION SITE PAIN (Soreness in injection arm), PRURITUS (Itchiness) and PRODUCT DOSE OMISSION ISSUE (Missed second dose) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 015M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history reported).    On 15-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Feb-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (Missed second dose). On an unknown date, the patient experienced ERYTHEMA (Redness on neck and chest), URTICARIA (Hives/Welts), VACCINATION SITE PAIN (Soreness in injection arm) and PRURITUS (Itchiness). On 15-Feb-2021, PRODUCT DOSE OMISSION ISSUE (Missed second dose) had resolved. At the time of the report, ERYTHEMA (Redness on neck and chest), URTICARIA (Hives/Welts), VACCINATION SITE PAIN (Soreness in injection arm) and PRURITUS (Itchiness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Relevant concomitant medications were not reported.  Treatment information was not provided.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Dizziness, Fatigue, Headache, Limb discomfort
Clinical narrative: 1 st dose on 27MAR2021 and has not received a second dose; Chest tightness; Painful; Dizziness; Headache; Body pains; Glands in throat swollen and painful/glands in under arm swollen and painful/lymph nodes swollen; Tired; Extreme arm pain; Hardly lift arm; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (1 st dose on 27MAR2021 and has not received a second dose), PAIN IN EXTREMITY (Extreme arm pain), LIMB DISCOMFORT (Hardly lift arm), CHEST DISCOMFORT (Chest tightness) and PAIN (Painful) in a 39-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 018B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Allergy to antibiotic (erythromycin) and Allergy to antibiotic (azithromycin).    On 27-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Mar-2021, the patient experienced PAIN IN EXTREMITY (Extreme arm pain), LIMB DISCOMFORT (Hardly lift arm), PAIN (Painful), DIZZINESS (Dizziness), HEADACHE (Headache), MYALGIA (Body pains), LYMPHADENOPATHY (Glands in throat swollen and painful/glands in under arm swollen and painful/lymph nodes swollen) and FATIGUE (Tired). On 29-Mar-2021, the patient experienced CHEST DISCOMFORT (Chest tightness). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (1 st dose on 27MAR2021 and has not received a second dose). The patient was treated with IBUPROFEN at an unspecified dose and frequency. On 27-Mar-2021, DIZZINESS (Dizziness) had resolved. On 29-Mar-2021, HEADACHE (Headache), MYALGIA (Body pains) and FATIGUE (Tired) had resolved. At the time of the report, PRODUCT DOSE OMISSION ISSUE (1 st dose on 27MAR2021 and has not received a second dose), PAIN IN EXTREMITY (Extreme arm pain), LIMB DISCOMFORT (Hardly lift arm), CHEST DISCOMFORT (Chest tightness), PAIN (Painful) and LYMPHADENOPATHY (Glands in throat swollen and painful/glands in under arm swollen and painful/lymph nodes swollen) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment details included three pills of ibuprofen for the pain in glands. Concomitant drugs and Lab data information, if any, not provided.   Most recent FOLLOW-UP information incorporated above includes: On 03-Aug-2021: Significant follow up On 11-Aug-2021: Non Significant information
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy, Myalgia, Pain, Pain in extremity, Product dose omission issue
Clinical narrative: 1 st dose on 27MAR2021 and has not received a second dose; Chest tightness; Painful; Dizziness; Headache; Body pains; Glands in throat swollen and painful/glands in under arm swollen and painful/lymph nodes swollen; Tired; Extreme arm pain; Hardly lift arm; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (1 st dose on 27MAR2021 and has not received a second dose), PAIN IN EXTREMITY (Extreme arm pain), LIMB DISCOMFORT (Hardly lift arm), CHEST DISCOMFORT (Chest tightness) and PAIN (Painful) in a 39-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 018B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Allergy to antibiotic (erythromycin) and Allergy to antibiotic (azithromycin).    On 27-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Mar-2021, the patient experienced PAIN IN EXTREMITY (Extreme arm pain), LIMB DISCOMFORT (Hardly lift arm), PAIN (Painful), DIZZINESS (Dizziness), HEADACHE (Headache), MYALGIA (Body pains), LYMPHADENOPATHY (Glands in throat swollen and painful/glands in under arm swollen and painful/lymph nodes swollen) and FATIGUE (Tired). On 29-Mar-2021, the patient experienced CHEST DISCOMFORT (Chest tightness). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (1 st dose on 27MAR2021 and has not received a second dose). The patient was treated with IBUPROFEN at an unspecified dose and frequency. On 27-Mar-2021, DIZZINESS (Dizziness) had resolved. On 29-Mar-2021, HEADACHE (Headache), MYALGIA (Body pains) and FATIGUE (Tired) had resolved. At the time of the report, PRODUCT DOSE OMISSION ISSUE (1 st dose on 27MAR2021 and has not received a second dose), PAIN IN EXTREMITY (Extreme arm pain), LIMB DISCOMFORT (Hardly lift arm), CHEST DISCOMFORT (Chest tightness), PAIN (Painful) and LYMPHADENOPATHY (Glands in throat swollen and painful/glands in under arm swollen and painful/lymph nodes swollen) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment details included three pills of ibuprofen for the pain in glands. Concomitant drugs and Lab data information, if any, not provided.   Most recent FOLLOW-UP information incorporated above includes: On 03-Aug-2021: Significant follow up On 11-Aug-2021: Non Significant information
Sex: M
Vaccine: COVID19, UNK
Symptoms: Chills, Fatigue, Pyrexia
Clinical narrative: Chills; Fatigue; Fever; This spontaneous case was reported by a consumer and describes the occurrence of CHILLS (Chills), FATIGUE (Fatigue) and PYREXIA (Fever) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No prior medical history was reported).    On 26-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Mar-2021, the patient experienced CHILLS (Chills), FATIGUE (Fatigue) and PYREXIA (Fever). At the time of the report, CHILLS (Chills), FATIGUE (Fatigue) and PYREXIA (Fever) was resolving.            No concomitant medications were provided.  Treatment details included acetaminophen.
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Injection site swelling, Pruritus
Clinical narrative: itchy arm; red arm; (arm) bumpy near injection site; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (itchy arm), ERYTHEMA (red arm) and INJECTION SITE SWELLING ((arm) bumpy near injection site) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046A21A and 001A21A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure and Cholesterol.   On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 2 dosage form. On 27-Mar-2021, the patient experienced PRURITUS (itchy arm), ERYTHEMA (red arm) and INJECTION SITE SWELLING ((arm) bumpy near injection site). At the time of the report, PRURITUS (itchy arm), ERYTHEMA (red arm) and INJECTION SITE SWELLING ((arm) bumpy near injection site) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Blister, Chills, Constipation, Dry skin, Influenza like illness
Clinical narrative: Chills; flu-like symptoms; lost all the skin on the palms of hands, except for right hand (not so many blisters on her fingers); Migraine; pain; loss of bowel control for two weeks; Swollen lymph nodes; roughness in her palms; some soreness at injection site; This spontaneous case was reported by a consumer and describes the occurrence of DRY SKIN (roughness in her palms), VACCINATION SITE PAIN (some soreness at injection site), CHILLS (Chills), INFLUENZA LIKE ILLNESS (flu-like symptoms) and BLISTER (lost all the skin on the palms of hands, except for right hand (not so many blisters on her fingers)) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 023M20A and 098A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Autoimmune disorder NOS (does not take medication for it).   On 12-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Mar-2021, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1. On 12-Feb-2021, the patient experienced DRY SKIN (roughness in her palms) and VACCINATION SITE PAIN (some soreness at injection site). On 13-Mar-2021, the patient experienced CHILLS (Chills), INFLUENZA LIKE ILLNESS (flu-like symptoms), PAIN (pain) and CONSTIPATION (loss of bowel control for two weeks). On an unknown date, the patient experienced BLISTER (lost all the skin on the palms of hands, except for right hand (not so many blisters on her fingers)), MIGRAINE (Migraine) and loss of bowel control for two weeks. The patient was treated with CELECOXIB (CELEBREX) for Pain management, at an unspecified dose and frequency and CLOBETASOL for Heavy feeling in arms & legs, at an unspecified dose and frequency. On 22-Feb-2021, DRY SKIN (roughness in her palms) had resolved. At the time of the report, VACCINATION SITE PAIN (some soreness at injection site), CHILLS (Chills), INFLUENZA LIKE ILLNESS (flu-like symptoms), MIGRAINE (Migraine), loss of bowel control for two weeks, PAIN (pain) and CONSTIPATION (loss of bowel control for two weeks) outcome was unknown.            No concomitant medications were provided   This case was linked to US-MODERNATX, INC.-MOD-2021-060821 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-060821:Dose2
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy, Migraine, Pain, Vaccination site pain
Clinical narrative: Chills; flu-like symptoms; lost all the skin on the palms of hands, except for right hand (not so many blisters on her fingers); Migraine; pain; loss of bowel control for two weeks; Swollen lymph nodes; roughness in her palms; some soreness at injection site; This spontaneous case was reported by a consumer and describes the occurrence of DRY SKIN (roughness in her palms), VACCINATION SITE PAIN (some soreness at injection site), CHILLS (Chills), INFLUENZA LIKE ILLNESS (flu-like symptoms) and BLISTER (lost all the skin on the palms of hands, except for right hand (not so many blisters on her fingers)) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 023M20A and 098A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Autoimmune disorder NOS (does not take medication for it).   On 12-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Mar-2021, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1. On 12-Feb-2021, the patient experienced DRY SKIN (roughness in her palms) and VACCINATION SITE PAIN (some soreness at injection site). On 13-Mar-2021, the patient experienced CHILLS (Chills), INFLUENZA LIKE ILLNESS (flu-like symptoms), PAIN (pain) and CONSTIPATION (loss of bowel control for two weeks). On an unknown date, the patient experienced BLISTER (lost all the skin on the palms of hands, except for right hand (not so many blisters on her fingers)), MIGRAINE (Migraine) and loss of bowel control for two weeks. The patient was treated with CELECOXIB (CELEBREX) for Pain management, at an unspecified dose and frequency and CLOBETASOL for Heavy feeling in arms & legs, at an unspecified dose and frequency. On 22-Feb-2021, DRY SKIN (roughness in her palms) had resolved. At the time of the report, VACCINATION SITE PAIN (some soreness at injection site), CHILLS (Chills), INFLUENZA LIKE ILLNESS (flu-like symptoms), MIGRAINE (Migraine), loss of bowel control for two weeks, PAIN (pain) and CONSTIPATION (loss of bowel control for two weeks) outcome was unknown.            No concomitant medications were provided   This case was linked to US-MODERNATX, INC.-MOD-2021-060821 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-060821:Dose2
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Rash, Vaccination site erythema, Vaccination site pain, Vaccination site pruritus, Vaccination site swelling
Clinical narrative: raised welts on her left arm from shoulder to elbow that went under her arm/rash; arm was red; arm was itchy; arm was warm; raised welts on her left arm from shoulder to elbow that went under her arm/rash; arm was sore; arm was swollen; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE PAIN (arm was sore), VACCINATION SITE SWELLING (arm was swollen), VACCINATION SITE ERYTHEMA (arm was red), VACCINATION SITE PRURITUS (arm was itchy) and VACCINATION SITE WARMTH (arm was warm) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event.    On 22-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Feb-2021, the patient experienced VACCINATION SITE PAIN (arm was sore) and VACCINATION SITE SWELLING (arm was swollen). On 01-Mar-2021, the patient experienced VACCINATION SITE ERYTHEMA (arm was red), VACCINATION SITE PRURITUS (arm was itchy), VACCINATION SITE WARMTH (arm was warm) and VACCINATION SITE URTICARIA (raised welts on her left arm from shoulder to elbow that went under her arm/rash). On an unknown date, the patient experienced RASH (raised welts on her left arm from shoulder to elbow that went under her arm/rash). On 25-Feb-2021, VACCINATION SITE PAIN (arm was sore) and VACCINATION SITE SWELLING (arm was swollen) had resolved. On 05-Mar-2021, VACCINATION SITE ERYTHEMA (arm was red), VACCINATION SITE PRURITUS (arm was itchy), VACCINATION SITE WARMTH (arm was warm) and VACCINATION SITE URTICARIA (raised welts on her left arm from shoulder to elbow that went under her arm/rash) had resolved. At the time of the report, RASH (raised welts on her left arm from shoulder to elbow that went under her arm/rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       no concomitant medications were provided treatment medications includes steroid shot sulfamethoxazole-trimethoprim 800/160mg   This case was linked to US-MODERNATX, INC.-MOD-2021-060480 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-060480:friend case
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site urticaria, Vaccination site warmth
Clinical narrative: raised welts on her left arm from shoulder to elbow that went under her arm/rash; arm was red; arm was itchy; arm was warm; raised welts on her left arm from shoulder to elbow that went under her arm/rash; arm was sore; arm was swollen; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE PAIN (arm was sore), VACCINATION SITE SWELLING (arm was swollen), VACCINATION SITE ERYTHEMA (arm was red), VACCINATION SITE PRURITUS (arm was itchy) and VACCINATION SITE WARMTH (arm was warm) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event.    On 22-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Feb-2021, the patient experienced VACCINATION SITE PAIN (arm was sore) and VACCINATION SITE SWELLING (arm was swollen). On 01-Mar-2021, the patient experienced VACCINATION SITE ERYTHEMA (arm was red), VACCINATION SITE PRURITUS (arm was itchy), VACCINATION SITE WARMTH (arm was warm) and VACCINATION SITE URTICARIA (raised welts on her left arm from shoulder to elbow that went under her arm/rash). On an unknown date, the patient experienced RASH (raised welts on her left arm from shoulder to elbow that went under her arm/rash). On 25-Feb-2021, VACCINATION SITE PAIN (arm was sore) and VACCINATION SITE SWELLING (arm was swollen) had resolved. On 05-Mar-2021, VACCINATION SITE ERYTHEMA (arm was red), VACCINATION SITE PRURITUS (arm was itchy), VACCINATION SITE WARMTH (arm was warm) and VACCINATION SITE URTICARIA (raised welts on her left arm from shoulder to elbow that went under her arm/rash) had resolved. At the time of the report, RASH (raised welts on her left arm from shoulder to elbow that went under her arm/rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       no concomitant medications were provided treatment medications includes steroid shot sulfamethoxazole-trimethoprim 800/160mg   This case was linked to US-MODERNATX, INC.-MOD-2021-060480 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-060480:friend case
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: Rash on her leg which spread to entire body; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of RASH (Rash on her leg which spread to entire body) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032M20A and 0BM20A) for COVID-19 vaccination.     No Medical History information was reported.   On 05-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 10-Mar-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced RASH (Rash on her leg which spread to entire body). The patient was treated with METHYLPREDNISOLONE for Rash, at an unspecified dose and frequency. On 25-Mar-2021, RASH (Rash on her leg which spread to entire body) had resolved.            Concomitant product use was not provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 15-Jun-2021: Follow-up information received on 15-JUN-2021 contains no new information
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Pain, Pyrexia, Vaccination site urticaria
Clinical narrative: hives around injection site; body aches; chills so bad and can't get warm; pounding headache; fever; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (body aches), CHILLS (chills so bad and can't get warm), HEADACHE (pounding headache), PYREXIA (fever) and VACCINATION SITE URTICARIA (hives around injection site) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 036A21A) for COVID-19 vaccination.     Concurrent medical conditions included Cancer.    On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Mar-2021, the patient experienced PAIN (body aches), CHILLS (chills so bad and can't get warm), HEADACHE (pounding headache) and PYREXIA (fever). On 26-Mar-2021, the patient experienced VACCINATION SITE URTICARIA (hives around injection site). At the time of the report, PAIN (body aches), CHILLS (chills so bad and can't get warm), HEADACHE (pounding headache), PYREXIA (fever) and VACCINATION SITE URTICARIA (hives around injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications were not provided. Treatment information was not provided.   Reporter did not allow further contact
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, Cough, Decreased appetite, Pyrexia
Clinical narrative: Coughing; loss of taste; anorexia; loss of smell; Fever; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (Coughing), AGEUSIA (loss of taste), DECREASED APPETITE (anorexia), ANOSMIA (loss of smell) and PYREXIA (Fever) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Mar-2021, the patient experienced COUGH (Coughing), AGEUSIA (loss of taste), DECREASED APPETITE (anorexia), ANOSMIA (loss of smell) and PYREXIA (Fever). At the time of the report, COUGH (Coughing), AGEUSIA (loss of taste), DECREASED APPETITE (anorexia), ANOSMIA (loss of smell) and PYREXIA (Fever) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not provided. Treatment information was not provided.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Lethargy
Clinical narrative: lethargic; overly tired; This spontaneous case was reported by a consumer and describes the occurrence of LETHARGY (lethargic) and FATIGUE (overly tired) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031A21A) for COVID-19 vaccination.     No Medical History Information was reported.  Concomitant products included ROSUVASTATIN CALCIUM (CRESTOR), ACETYLSALICYLIC ACID (BABY ASPIRIN), FEXOFENADINE HYDROCHLORIDE (ALLEGRA), MULTIVITAMIN [VITAMINS NOS] and VITAMIN D3 for an unknown indication.    On 26-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Mar-2021, the patient experienced LETHARGY (lethargic) and FATIGUE (overly tired). The patient was treated with PARACETAMOL (TYLENOL) at a dose of 1000 mg once. On 28-Mar-2021, LETHARGY (lethargic) and FATIGUE (overly tired) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       This case was linked to MOD-2021-060860 (Patient Link).
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Blood pressure measurement, Dizziness
Clinical narrative: dizziness; weakness; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (dizziness) and ASTHENIA (weakness) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 29-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced DIZZINESS (dizziness) and ASTHENIA (weakness). At the time of the report, DIZZINESS (dizziness) and ASTHENIA (weakness) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 29-Mar-2021, Blood pressure measurement: 89/59 (abnormal) 89/59.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication is provided. No treatment medications were reported.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Nausea, Pain in extremity, Paraesthesia oral
Clinical narrative: sore arm; slight Headache; fatigue; slight nausea; Woke up the next morning (Saturday); the tingling appeared to be gone. When I began talking with Four hours later (approximately 12:00 noon), the tingling remained, again, no better, but no worse. I decided to visit the E.R.; This spontaneous case was reported by a consumer and describes the occurrence of PARAESTHESIA ORAL (Woke up the next morning (Saturday); the tingling appeared to be gone. When I began talking with Four hours later (approximately 12:00 noon), the tingling remained, again, no better, but no worse. I decided to visit the E.R.), PAIN IN EXTREMITY (sore arm), HEADACHE (slight Headache), FATIGUE (fatigue) and NAUSEA (slight nausea) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007B21A) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: FLU (Nasal passages completed blocked and swollen with full-blown flu symptoms for 36 hours 13 years ago) and flu vaccine (Tingling in back of tongue 23 years ago). Past adverse reactions to the above products included Adverse reaction with FLU and flu vaccine. Concurrent medical conditions included Osteoarthritis since 06-Jan-2012, Hypertension since 07-Jan-1994, Drug allergy (Linopril), Drug allergy (Diflucan), Latex allergy and Allergy to nuts (Walnuts). Concomitant products included HYDROCHLOROTHIAZIDE, VALSARTAN (VALSARTAN & HCTZ), GABAPENTIN from 02-Jan-2021 to an unknown date, FEXOFENADINE HYDROCHLORIDE (ALLEGRA) and FLUTICASONE PROPIONATE (FLONASE ALLERGY RELIEF) for an unknown indication.    On 26-Mar-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Mar-2021, the patient experienced PARAESTHESIA ORAL (Woke up the next morning (Saturday); the tingling appeared to be gone. When I began talking with Four hours later (approximately 12:00 noon), the tingling remained, again, no better, but no worse. I decided to visit the E.R.). On an unknown date, the patient experienced PAIN IN EXTREMITY (sore arm), HEADACHE (slight Headache), FATIGUE (fatigue) and NAUSEA (slight nausea). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL A) at an unspecified dose and frequency. On 28-Mar-2021, PARAESTHESIA ORAL (Woke up the next morning (Saturday); the tingling appeared to be gone. When I began talking with Four hours later (approximately 12:00 noon), the tingling remained, again, no better, but no worse. I decided to visit the E.R.) had resolved. At the time of the report, PAIN IN EXTREMITY (sore arm), HEADACHE (slight Headache), FATIGUE (fatigue) and NAUSEA (slight nausea) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Most recent FOLLOW-UP information incorporated above includes: On 20-Jul-2021: Relevant history was added, Concomitant and treatment medications were added, Outcome of events was updated , new events added.
Age: 15.0
Sex: M
Vaccine: COVID19
Symptoms: Body mass index, Product administered to patient of inappropriate age
Clinical narrative: 15 year old patient mistakenly received Moderna vaccine; This spontaneous case was reported by an other and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (15 year old patient mistakenly received Moderna vaccine) in a 15-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011A21A) for COVID-19 vaccination.     Concurrent medical conditions included Autism.    On 01-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Mar-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (15 year old patient mistakenly received Moderna vaccine). On 01-Mar-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (15 year old patient mistakenly received Moderna vaccine) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body mass index: 95 percentile.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment related information has been reported.; Sender's Comments: This report refers to a case of product administered to patient of inappropriate age (15 year old) for mRNA-1273 (lot number 011A21A) with no associated AEs reported.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Lethargy
Clinical narrative: lethargic; overly tired; This spontaneous case was reported by a consumer and describes the occurrence of LETHARGY (lethargic) and FATIGUE (overly tired) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031A21A) for COVID-19 vaccination.     Medical history is not provided by the Reporter.  Concomitant products included ROSUVASTATIN CALCIUM (CRESTOR), ACETYLSALICYLIC ACID (BABY ASPIRIN), FEXOFENADINE HYDROCHLORIDE (ALLEGRA), VITAMIN D3 and MULTIVITAMINS [VITAMINS NOS] for an unknown indication.    On 26-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Mar-2021, the patient experienced LETHARGY (lethargic) and FATIGUE (overly tired). The patient was treated with PARACETAMOL (TYLENOL) at a dose of 1000 milligram once a day. On 28-Mar-2021, LETHARGY (lethargic) and FATIGUE (overly tired) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Exposure during pregnancy, Pain in extremity, Pregnancy test
Clinical narrative: Sore arm; Pregnant patient received vaccine when she was 19 weeks and 3 days pregnant; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of EXPOSURE DURING PREGNANCY (Pregnant patient received vaccine when she was 19 weeks and 3 days pregnant) and PAIN IN EXTREMITY (Sore arm) in a 36-year-old female patient (gravida 3) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037A21B) for COVID-19 vaccination.     Concomitant products included PRENATAL VITAMINS [ASCORBIC ACID;BETACAROTENE;CALCIUM SULFATE;COLECALCIFEROL;CYANOCOBALAMIN;FERROUS FUMARATE;FOLIC ACID;NICOTINAMIDE;PYRIDOXINE HYDROCHLORIDE;RETINOL ACETATE;RIBOFLAVIN;THIAMINE MONONITRATE;TOCOPHERYL ACETATE;ZINC OXIDE] for an unknown indication.    On 24-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 05-Nov-2020 and the estimated date of delivery was 16-Aug-2021. On 16-Nov-2020, the patient experienced EXPOSURE DURING PREGNANCY (Pregnant patient received vaccine when she was 19 weeks and 3 days pregnant). On 25-Mar-2021, the patient experienced PAIN IN EXTREMITY (Sore arm). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  nineteenth week of the pregnancy.  At the time of the report, EXPOSURE DURING PREGNANCY (Pregnant patient received vaccine when she was 19 weeks and 3 days pregnant) had resolved and PAIN IN EXTREMITY (Sore arm) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 16-Nov-2020, Pregnancy test: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment medications were provided
Age: 54.0
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site mass, Vaccination site swelling
Clinical narrative: lump and swelling up under my arm after the second shot; lump and swelling up under my arm after the second shot; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE MASS (lump and swelling up under my arm after the second shot) and VACCINATION SITE SWELLING (lump and swelling up under my arm after the second shot) in a 54-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for an unknown indication.     The patient's past medical history included No adverse event.   On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 26-Mar-2021, the patient experienced VACCINATION SITE MASS (lump and swelling up under my arm after the second shot) and VACCINATION SITE SWELLING (lump and swelling up under my arm after the second shot). At the time of the report, VACCINATION SITE MASS (lump and swelling up under my arm after the second shot) and VACCINATION SITE SWELLING (lump and swelling up under my arm after the second shot) had not resolved.            No concomitant medications were provided No treatment medications were provided Action taken with mRNA-1273 is not applicable   Reporter did not allow further contact
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: Dissociation, Euphoric mood, Feeling abnormal, Tinnitus
Clinical narrative: feels like a ghost and feels disconnected from the body and described the his symptoms as; had brain fog; tinnitus (ringing in the ear).; The patient was driving and passed high feeling; This spontaneous case was reported by a consumer and describes the occurrence of EUPHORIC MOOD (The patient was driving and passed high feeling), FEELING ABNORMAL (had brain fog), DISSOCIATION (feels like a ghost and feels disconnected from the body and described the his symptoms as) and TINNITUS (tinnitus (ringing in the ear).) in a 59-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Post-traumatic stress disorder (Takes Anxiety medications for sleep).    On 01-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Mar-2021, the patient experienced EUPHORIC MOOD (The patient was driving and passed high feeling). On 25-Mar-2021, the patient experienced TINNITUS (tinnitus (ringing in the ear).). On 29-Mar-2021, the patient experienced FEELING ABNORMAL (had brain fog). On an unknown date, the patient experienced DISSOCIATION (feels like a ghost and feels disconnected from the body and described the his symptoms as). At the time of the report, EUPHORIC MOOD (The patient was driving and passed high feeling), FEELING ABNORMAL (had brain fog), DISSOCIATION (feels like a ghost and feels disconnected from the body and described the his symptoms as) and TINNITUS (tinnitus (ringing in the ear).) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported. No treatment medications were reported.  Symptoms: Patient reported that he had experienced COVID like symptoms post vaccination.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Sore arm; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Sore arm) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L20A) for COVID-19 vaccination.     Concomitant products included ATENOLOL and ESCITALOPRAM OXALATE (LEXAPRO) for an unknown indication.    On 09-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Feb-2021, the patient experienced VACCINATION SITE PAIN (Sore arm). At the time of the report, VACCINATION SITE PAIN (Sore arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Other concomitant products included medications for hormone replacement therapy. Treatment information was not provided.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site swelling, Vaccination site warmth
Clinical narrative: injection site had fever; swelled up with rough bumpy skin; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (injection site had fever) and VACCINATION SITE SWELLING (swelled up with rough bumpy skin) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 046A21A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE WARMTH (injection site had fever) and VACCINATION SITE SWELLING (swelled up with rough bumpy skin). The patient was treated with IBUPROFEN at an unspecified dose and frequency. At the time of the report, VACCINATION SITE WARMTH (injection site had fever) and VACCINATION SITE SWELLING (swelled up with rough bumpy skin) outcome was unknown. Not Provided          The action taken with mRNA (Moderna COVID-19) (Unknown) was Not Applicable Concomitant medications were not provided.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Second dose is rescheduled 47 days out from the first dose; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose is rescheduled 47 days out from the first dose) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032M20A and 027B21A) for COVID-19 vaccination.     No Medical History Information was reported.  Concomitant products included METOPROLOL, ATORVASTATIN CALCIUM (LIPITOR), LEVOTHYROXINE, OMEPRAZOLE (PRILOSEC [OMEPRAZOLE]) and VITAMIN D3 for an unknown indication.   On 11-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 11-Mar-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose is rescheduled 47 days out from the first dose). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose is rescheduled 47 days out from the first dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment medications were reported.   This case was linked to US-MODERNATX, INC.-MOD-2021-060640 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 25-Jun-2021: Follow up received on 25-JUN-2021 - Second dose and contact details updated .; Sender's Comments: Very limited information regarding this event has been provided at this time. US-MODERNATX, INC.-MOD-2021-060640:Same reporter (MOD21-064572)
Age: 79.0
Sex: M
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Patient took 2nd dose over 42 after the 1st dose; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient took 2nd dose over 42 after the 1st dose) in a 79-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 029L20A and 029K20A) for COVID-19 vaccination.     No Medical History information was reported.   On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 19-Mar-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient took 2nd dose over 42 after the 1st dose). On 19-Mar-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient took 2nd dose over 42 after the 1st dose) had resolved.            No concomitant medications were reported. Treatment medications were not provided by the reporter. Action taken with mRNA-1273 in response to the events were not Applicable.   Most recent FOLLOW-UP information incorporated above includes: On 15-Jun-2021: Non-significant followup added to include AE contact information.
Sex: F
Vaccine: COVID19
Symptoms: Feeling abnormal, Injection site erythema, Injection site pain
Clinical narrative: red area at the injection site; felt out of sorts; soreness at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of FEELING ABNORMAL (felt out of sorts), INJECTION SITE ERYTHEMA (red area at the injection site) and INJECTION SITE PAIN (soreness at the injection site) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 24-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Mar-2021, the patient experienced INJECTION SITE PAIN (soreness at the injection site). On 25-Mar-2021, the patient experienced FEELING ABNORMAL (felt out of sorts). On 28-Mar-2021, the patient experienced INJECTION SITE ERYTHEMA (red area at the injection site). At the time of the report, FEELING ABNORMAL (felt out of sorts), INJECTION SITE ERYTHEMA (red area at the injection site) and INJECTION SITE PAIN (soreness at the injection site) outcome was unknown.            Action taken with mRNA-1273 was not applicable. No concomitant medication was reported. No treatment information was provided.
Sex: U
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Patient received first dose 48 days ago; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a pharmacist (subsequently medically confirmed) and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received first dose 48 days ago) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received first dose 48 days ago). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received first dose 48 days ago) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment medication were not reported. Concomitant medication were not reported.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Miliaria, Pruritus, Rash, Skin reaction
Clinical narrative: Skin reaction; Prickly; Itching; Burning red rash on chest and back; This spontaneous case was reported by a consumer and describes the occurrence of SKIN REACTION (Skin reaction), MILIARIA (Prickly), PRURITUS (Itching) and RASH (Burning red rash on chest and back) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047a21a) for COVID-19 vaccination.     No Medical History information was reported.   On 27-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 27-Feb-2021, the patient experienced SKIN REACTION (Skin reaction), MILIARIA (Prickly), PRURITUS (Itching) and RASH (Burning red rash on chest and back). At the time of the report, SKIN REACTION (Skin reaction), MILIARIA (Prickly), PRURITUS (Itching) and RASH (Burning red rash on chest and back) outcome was unknown.            Action taken with mRNA-1273 in response to the events was not Applicable.  Concomitant product use was not provided by the reporter. Treatment information was not provided.   This case was linked to MOD-2021-061043.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Hypoaesthesia
Clinical narrative: Face felt numb; Red face; Felt like novocaine; This spontaneous case was reported by a consumer and describes the occurrence of HYPOAESTHESIA (Face felt numb), ERYTHEMA (Red face) and HYPOAESTHESIA (Felt like novocaine) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 29-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Mar-2021, the patient experienced HYPOAESTHESIA (Face felt numb), ERYTHEMA (Red face) and HYPOAESTHESIA (Felt like novocaine). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) (oral) at a dose of 2 dosage form. On 29-Mar-2021, ERYTHEMA (Red face) had resolved. At the time of the report, HYPOAESTHESIA (Face felt numb) and HYPOAESTHESIA (Felt like novocaine) had not resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication was not reported.
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Pain
Clinical narrative: Achy; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Achy) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 057G20A and 012A21A) for COVID-19 vaccination.     Concomitant products included LOSARTAN, METOPROLOL SUCCINATE and ATORVASTATIN for an unknown indication.   On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PAIN (Achy). At the time of the report, PAIN (Achy) had resolved.            Action taken with vaccine was not applicable.  No treatment information was provided.
Sex: U
Vaccine: COVID19
Symptoms: Ageusia
Clinical narrative: Loss of tastebuds; This spontaneous case was reported by a consumer and describes the occurrence of AGEUSIA (Loss of tastebuds) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Mar-2021, the patient experienced AGEUSIA (Loss of tastebuds). At the time of the report, AGEUSIA (Loss of tastebuds) had not resolved. Not Provided          The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was not applicable.  No relevant concomitant medications were reported.   Treatment information was not provided.